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Abstract
Background: An injection of estradiol valerate (EV) provides estradiol for a prolonged period.
Recent research indicates that a single 2.0 mg injection of EV modifies a female rat's appetite for
alcoholic beverages. This research extends the initial research by assessing 8 doses of EV (from .001
to 2.0 mg/female rat), as well assessing the effects of 2.0 mg EV in females with ovariectomies.
Results: With the administration of EV, there was a dose-related loss of bodyweight reaching the
maximum loss, when it occurred, at about 4 days after injections. Subsequently, rats returned to
gaining weight regularly. Of the doses tested, only the 2.0 mg dose produced a consistent increase
in intake of ethanol during the time previous research indicated that the rats would show enhanced
intakes. There was, however, a dose-related trend for smaller doses to enhance intakes. Rats with
ovariectomies showed a similar pattern of effects, to intact rats, with the 2 mg dose. After extensive
histories of intake of alcohol, both placebo and EV-treated females had estradiol levels below the
average measured in females without a history of alcohol-intake.
Conclusion: The data support the conclusion that pharmacological doses of estradiol can produce
enduring changes that are manifest as an enhanced appetite for alcoholic beverages. The effect can
occur among females without ovaries.
Background
Large doses of estradiol valerate (EV) deliver estradiol for
2 to 4 weeks. The released estradiol will have the same
effects as estradiol delivered by other means; except, of
course, for effects that accrue from the delivery of supra-
physiological doses for an extended period [1]. A single
large dose of EV (i.e., 2 mg/female rat) is reported to be
toxic to the arcuate nucleus of the hypothalamus, thereby
disrupting production of β-endorphin [2-4].
In the interest of determining the effects of reduced β-
endorphin on appetite for alcoholic beverages, Reid et al.
[5] provided female rats a daily opportunity to take sweet-
ened alcoholic beverage. After the females had developed
the habit of taking considerable alcohol daily, they were
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given EV (2 mg). The initial effect was a reduction in
intake of alcohol, a finding concordant with the observa-
tions of others [6,7] and with some theory of the relation-
ship of opioids to appetite for alcoholic beverages [8].
With the continuance of the daily opportunities to take
alcoholic beverages, however, a different picture emerged.
The EV-treated females gradually increased their intakes
until they were taking more alcohol than the placebo-
treated. Further, the enhanced intakes, once they emerged,
were sustained for months after the single injection of EV
[5,9].
Many events will reduce rats' intakes of alcoholic bever-
ages, e.g., those associated with illness or a malaise. Only
a few circumstances enhance appetite for ethanol for a
sustained period. Given that an enhanced appetite for eth-
anol is the prime circumstance of alcohol abuse and alco-
holism (AAA), the fact that a hormonal manipulation led
to large, sustained intakes of an alcoholic beverage moti-
vated further investigation. Further research [5,9,10]
determined that the enhanced intake of ethanol was not
specific to a particular strain of rats and not specific to a
particular alcoholic beverage (i.e., increased intakes
occurred with both sweetened and unsweetened alcoholic
beverages and with different concentrations of ethanol).
The increases in intake of ethanol were seen when alco-
holic beverages were presented for 2 hr a day or when pre-
sented for 24 hr a day. The grams of ethanol per kilogram
of body weight (g'E/kg) taken by EV-treated female rats
can reach very large amounts. For example, when EV-
treated females were presented with a saccharin-sweet-
ened alcoholic beverage, for 24 hr a day from 1 to 3
months after a single injection of 2.0 mg of EV, 40% of
them took over 8 g'E/kg a day, with the balance taking
considerable amounts as well [9].
Are the enhanced appetites that emerge following a dose
of EV specific to alcoholic beverages or might they occur
with any beverage taken daily? To get germane informa-
tion, female rats were given a daily opportunity to take
saccharin solutions [11]. One group was provided with a
solution taken avidly and one was provided with a con-
centrated solution that was taken only modestly (to the
human taste, it is bitter sweet). Half of the females were
given the same dose of EV that enhanced intakes of alco-
holic beverages and the other half were given placebos.
The single dose of EV enhanced intakes of the more palat-
able saccharin solution, but decreased intakes of the less
palatable solution. The conclusion is that EV can enhance
intakes of highly palatable, reinforcing ingesta, but not
intakes of all ingesta.
Following a single injection of EV, 2.0 mg/rat, there is
weight-loss across the first few days. Then, there is a
resumption of weight-gain with nearly the same rate of
gain as placebo controls [5,9,11]. The changes in weight
are interesting, because they probably reflect underlying
conditions that affect appetite. The initial loss of weight
may index a malaise that could be conditioned to pre-
sented ingesta. If a malaise is a possibility with injections
of estradiol (as indexed by weight loss), then the conclu-
sion that estradiol reduces intake of alcoholic beverages
[6,7] and intake of other ingesta [12] may be related to a
conditioned food avoidance [13,14]. As the malaise and
consequent food avoidance wanes, however, the continu-
ance of estradiol enhances intake of alcoholic beverages.
As mentioned, many events can reduce rats' intakes of
alcohol (e.g., a malaise), but only a few events, pro-
grammed in the laboratory, increase rats' intakes. One
reliable variable for increasing alcohol-intake is extended
opportunities to take alcoholic beverages. Another relia-
ble variable, for increasing intake, is to make the alcoholic
beverage palatable (e.g., by adding sweeteners [15] or the
taste of beer [16]). Yet another variable that will increase
intakes is to deprive rats of food or water before opportu-
nity to take food and water as well as alcoholic bever-
age[17]. The hunger and thirst seem to set a condition that
increases the ingestion of alcoholic beverage even though
intake of food or water is the first priority. Similarly, rats
take more alcoholic beverage when presented during the
time they ordinarily eat and drink the most (during the
first part of the dark cycle) compared to the same duration
at other times. After sleep, they are usually food and water
deprived for a number of hours. During the initial arousal
of their day, they drink, eat, groom and, if alcoholic bev-
erages are available, take the [18]. Female rats, on average
in terms of g'E/kg, take more ethanol than the males of the
same strain [19-21]. As will be demonstrated here, these
variables can be combined (present a sweetened alcoholic
beverage for a number of days at the time when female
rats usually eat and drink) to induce large intakes of etha-
nol. Will doses of EV, other than those used initially,
induce further increases in intakes? Only two doses of EV
have been assessed, 2.0 and 1.0 mg per rat [5,9,10]. A pur-
pose of this study is to test more doses. If smaller doses
increase intakes, then it is more likely that the doses of
estradiol used by women might enhance appetite for alco-
holic beverages.
There is theory indicating that the toxicity associated with
large doses of EV is a product of an interaction with the
ovaries [22]. In light of those ideas, we performed ovariec-
tomies on one group before getting their EV (2 mg) and
compared their intakes to intact females.
It is known that large doses of EV reduce bodyweight, or
retard the usual gain in weight seen among young female
rats, for a number of days following injections. It is also
known that doses of estradiol can induce a conditionedBMC Pharmacology 2007, 7:3 http://www.biomedcentral.com/1471-2210/7/3
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food avoidance and a conditioned place aversion [13,14].
To reduce the possibility that the negative events just fol-
lowing injections of EV will be associated with the alco-
holic beverage used, we presented the alcoholic beverage
6 days following the injections.
Results
Experiment 1: Doses of EV and Intake of Sweetened 
Alcoholic (12% ethanol) Beverage
The 10 rats who received ovariectomies did not gain
weight on the day following surgery, but thereafter
showed the characteristic trend toward gaining more
weight than their intact counterparts. All rats received
their injections (EV in carrier or EV's carrier) after they
were weighed on the 6th day after the surgeries of ovariec-
tomies.
Figure 1 summarizes the initial effects of doses on body-
weights. As expected for healthy, young rats living in cages
by themselves with food and water always available, the
placebo controls gained about 1% of their bodyweight
daily. Generally, the larger doses induced a loss in weight
that reached a maximum at about 4 days after the injec-
tions. Subsequent to the initial loss of weight, the rats
gained weight regularly. The pattern of loss and return to
regular weight gain, for the doses of 1 and 2 mg/rat, are
very similar to that reported in Reid et al. [5]. As expected,
EV prevented the rapid weight gain associated with ova-
riectomies.
Six days after injections, all rats were presented with
sweetened alcoholic beverage for the 6 hr of initial dark-
ness of a daily light-dark cycle. The beverage (12% etha-
nol, by weight) was presented on Tues., Wed., Thurs., and
Fri. of each week. Figure 2 presents the progression in
intake of alcoholic beverage, in terms g'E/kg, for the pla-
cebo controls and the two groups of the smallest doses
(those showing no weight loss with injections). Notice
that intakes were modest during the first week, but gradu-
ally increased during the next two. By the 4th and 5th week,
intakes were substantial. If EV were to induce an incre-
ment in taking alcoholic beverage, it would have to
increase already large intakes associated with this kind of
regimen.
Figure 3 presents the salient findings with intake of etha-
nol across doses, excluding the ovariectomized subjects.
Initial analyses, by way of ANOVA for repeated measures,
indicated that all main effects (doses, the factor associated
with weekly scores, and the factor associated with days
within weeks) and interactions were reliable sources of
variance, indicating further analyses were appropriate.
With respect to gain in bodyweights (Figure 2) and data of
intakes, at no comparison were scores of the placebo
group and groups getting EV at 0.001 and 0.003 statisti-
cally different from one another. Consequently, these
three groups were combined to obtain an enlarged control
group, labeled placebo in some figures (n = 30) to further
assess the effects of doses on intakes.
To further assess the effects of doses on intakes, an
ANOVA for repeated measures was done using the mean
intakes for each week of the first 5 weeks of presentation
of alcoholic beverage using the enlarged placebo-control
group and each of the groups getting larger doses. The
ANOVA yields for the repeated measures of weeks F(4, 28)
= 141.28, p < 0.0001, showing that intakes increase as
weeks of presentation continue (this main effect is shown
in Fig. 2). The values for the group effect (doses) are
F(7,92) = 2.12, p = 0.05. The values associated with the
interaction are F(28,368) = 1.82, p = 0.008. The ANOVA
indicates it is appropriate to look for simple main effects
(doses) at each week.
The one way ANOVAs for simple main effects at Weeks 1,
2 and 3 indicate that groups were not reliably different
from one another. Similar ANOVAs, however, yielded val-
ues indicating significant differences among groups at
Weeks 4 and 5. For Week 4, the values are F(6,83) = 3.69,
p = 0.003; for Week 5, F(6,83) = 2.03, p = 0.07. These
Changes in Bodyweights with Various Doses of EV Figure 1
Changes in Bodyweights with Various Doses of EV. 
Mean ratios using baseline (the weight of the rats just before 
injections) and the mean of Day 4 after injections (after) to 
obtain a % change in bodyweight across doses of EV. A ratio 
greater than 1 indicates that the subjects gained weight and a 
ratio less than 1 indicates that subjects lost weight. The mean 
weight across all rats just before injections was 223.5 g and it 
was arranged so that the groups' weights were nearly the 
same before injections. N = 10 females a group. The lines 
above the bars depict standard errors of the means. The two 
darkest gray bars denote p-values associated with t-test com-
parisons to the placebo values and those values are ps > 0.75. 
The p-values associated with the lighter gray bars range from 
0.04 to 0.01. The p-values associated with doses depicted by 
the white bars are ps < 0.0000001.
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results indicate that it is appropriate to compare scores for
each dose with one another. Using Fisher's test for post
hoc comparisons, the scores of placebo were compared
with each dose of EV for each week. With one exception,
only the scores associated with the 2 mg dose meet stand-
ards for being statistically significant (ps < 0.05), but
notice that the trends indicate a dose-response relation-
ship. It may be, as indicated by the significant value asso-
ciated with the 0.1 mg EV-value (middle panel of Figure
3), that the largest effect on intake for any given dose may
only be at certain times and those effects may wane across
time.
Figure 4 serves two purposes. Analyses of the intake data
(some of which are depicted in Figure 3) indicated that
there were statistically significant differences among days
within weekly blocks. To depict the kind of scores leading
to those statistically significant effects, the scores for days
within weeks are presented for some of the groups (Figure
4). Although the change in scores following periods of no
alcoholic beverage (withdrawal) to those when alcohol is
again provided are of interest to theory concerning the rel-
evance of those changes to relapse to drinking large
amounts of alcohol (the so-called alcohol deprivation
effect), the interest here is only on estradiol's potential
effects. Further analyses of the effects associated with the
factor of days are not presented here. The effects of ova-
riectomies are also summarized in Figure 4.
Did ovariectomies modify the effects of EV, 2 mg? To
address that, we compared intakes of three groups: (a)
intact females who received 2 mg of EV, (b) females who
received both ovariectomies and 2 mg of EV, and (c) the
enlarged placebo group (placebo, 0.001 and 0.003 doses
of EV) using weekly means for each 5 weeks of alcohol
availability. The data-set corresponds to a 3 by 5 ANOVA
The progression of intake of ethanol across weeks Figure 2
The progression of intake of ethanol across weeks. This figure depicts mean intake of ethanol as a function of week of 
presentation of the alcoholic beverage for the placebo-control group and the two groups getting the smallest doses of EV (an 
enlarged control group). Notice that there is a marked increase in intake from the 1st week to the 2nd and from the 2nd to the 
3rd. Intakes tend to stabilize across the 3rd to 5th week. This pattern of increases is typical of rats presented palatable alcoholic 
beverage. Other data [e.g., 5] indicate that, without any further intervention, intakes increase only slightly beyond those of the 
5th week of opportunity to take palatable alcoholic beverages.
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for repeated measures with factors for the three groups of
subjects and 5 weeks of intakes. An ANOVA of the data
associated with the factor of weeks of testing yields an
F(4,8) = 50.57, p < 0.0001, indicating again (Figure 2)
that intakes progress across weeks of opportunity to drink.
The values from the ANOVA for the group effect are
F(2,47) = 5.02, p = 0.01. The interaction was not a reliable
source of variance. The statistically significant group effect
indicates that further comparisons among groups are
appropriate.
Using post hoc adjustment of critical differences for mul-
tiple comparisons, further analysis indicated that the
intact females getting 2 mg of EV differed from the con-
trols (p = 0.008), as expected from the previous presenta-
tion of the findings. The analysis indicated that the group
with ovariectomies getting 2 mg of EV drank more alco-
holic beverage than controls (p = 0.03). There was no
indication that the two groups getting EV differed signifi-
cantly from one another (p = 0.65). In brief, the analysis
supports the conclusion that EV, 2 mg, enhances intakes
of alcoholic beverage in both intact and ovariectomized
females.
Figure 5 is another way of characterizing the effects of
large doses of EV. It is a tally of the number of subjects tak-
ing more ethanol than the placebo-control subject that
took the most. Five females of the 2 mg dose of EV drank
more than 80 g'E/kg during the 20 days of opportunity to
do so, i.e., more than 80 g'E/kg during the 120 hr of
opportunity to drink; more than 0.6 g'E/kg an hour.
Experiment 2: Presentation of 18% Ethanol in Sugar Water 
to Rats Given High Doses of EV and Placebo Controls
We have assessed the effects of EV using a variety of kinds
of alcoholic beverages. We have not, however, used a bev-
erage with a concentration more than 12% ethanol
(weight to weight). To see what would happen when a
concentration of 18% was presented, we continued to
assess intakes of sweetened alcoholic beverage using four
groups of Experiment 1: (a) the group of 2 mg of EV, (b)
of 2 mg with ovariectomies, (c) of 1 mg of EV, and (d) pla-
cebo-controls. After the 6 weeks of the weekly regimen of
Experiment 1, the subjects continued testing with the only
change being that the alcoholic beverage was 18% rather
than 12%.
Figure 6 summarizes the results of introducing the more
concentrated ethanol solution. During the first week of
exposure to the 18% beverage, all four groups took large
amounts of ethanol. During the 2nd week, however, the
placebo controls reduced their intakes while the subjects
of EV did not. The high levels of intake of the 2 mg EV
group occurred more than 50 days after the single injec-
tion of EV. The ovariectomized females drank more, on
average, than the placebo controls on every day of testing.
Experiment 3: Measures of Circulating Estradiol and 
Autopsy Results
At the end of measures of ethanol intake (Experiment 2),
we took vaginal smears daily for 12 days from the females
of 2 mg EV (only intact), 1 mg EV and placebo controls.
After histological inspection of the cells of those smears,
Mean Grams of Ethanol Taken Daily during Weekly Presentation of Alcoholic Beverage Figure 3
Mean Grams of Ethanol Taken Daily during Weekly Presentation of Alcoholic Beverage. This figure presents a 
summary of the effects of the various doses on intake of alcoholic beverages by presenting the mean weekly intake of the 
females during the 3rd, 4th and 5th week of presentation of alcoholic beverage. The data point labelled placebo is the mean of the 
groups getting no EV and the two groups getting the smallest doses of EV (0.001 and 0.003 mg/female). The bars are standard 
errors of the mean. The lines without data-points are trend lines of best fit to the data.
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the idea was to determine what day during the estrous
cycle the females were on when we sacrificed them while
taking samples of blood. The idea was to be able to com-
pare the circulating estradiol values to known standards
(which, of course, vary across the days of the cycle) as well
as the values among the groups.
On the day of the last vaginal smear, the females were sac-
rificed and trunk blood taken to measure circulating levels
of estradiol. When we sacrificed the females, we also
inspected the area of the ovaries of the subjects given ova-
riectomies.
The autopsy indicated that there were no signs of ovaries
in nine of the ten females that received surgeries. One of
the ten had a very small remnant of ovary on one side
which was so small that we included this subject in all
analyses of the data. These observations, plus the low level
of circulating estradiol (mean = 10.4 pg/ml), indicate that
the surgeries accomplished the goal of removing the ova-
ries.
After inspection of the vaginal smears, the conclusion was
reached that the females given EV (1 or 2 mg) and place-
bos and exposed to a lengthy regimen of intake of alcohol
were not cycling, at least, not regularly or in any discerni-
ble pattern. Furthermore, as can be seen from an inspec-
tion of means and the large standard deviations of
circulating estradiol (Table 1), there was no statistically
significant difference among the groups despite the fact
that some had ovariectomies and some had only place-
bos. Evidently, the regimen of alcohol availability and the
intake of large amounts of alcoholic beverage, when avail-
able, had a profound effect on the production of estradiol
by the intact females.
Experiment 4: Intakes immediately following 2 mg EV 
injections
When rats have had many days to take sweetened alco-
holic beverages, they gradually increase their intakes over
about 3 weeks and then their intakes tend to stabilize
(placebo-values depicted in Figure 2 and 4). In a group of
rats that had stable, high levels of intakes of saccharin
Mean Grams of Ethanol Taken for Each Day of Presentation of 12% Ethanol Solution for Three Groups of Subjects Figure 4
Mean Grams of Ethanol Taken for Each Day of Presentation of 12% Ethanol Solution for Three Groups of Sub-
jects. The mean intakes for each day of presentation of alcoholic beverage for three groups of subjects, a placebo-control 
group and two groups that had received 2 mg of estradiol valerate (n = 10 a group), one of which had ovariectomies. Notice 
that there is considerable variation associated with days within weeks. More importantly, notice that the intakes of the two 
groups receiving 2 mg of EV drank more during the 3rd, 4th, and 5th week of opportunity to do so.
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sweetened alcoholic beverage, 2 mg of EV markedly
reduced intakes. Intakes gradually increased and eventu-
ally became more than before injections and more than
those given placebos [5]. EV, 2 mg/rat, reduced intakes of
a saccharin solution (no ethanol), but produced less
reduction in intake of a sugar solution [11]. This experi-
ment asked whether the 2 mg EV also reduced the steady
intake of females taking a sugar sweetened alcoholic bev-
erage.
The subjects were those who had received 0.001 and
0.003 mg of EV in Experiment 1. At the end of the first 5
weeks of opportunity to drink, they were drinking nearly
the same amount as placebo controls. They were then ran-
domly assigned to get either 2 mg of EV or placebos.
The subjects that received EV lost weight in nearly the
same amount and pattern as those of 2 mg, Experiment 1.
The results, g'E/kg, are depicted in Figure 7. As can be seen,
the group getting EV markedly reduced their intake during
the week just following their injections. These results are
similar to those obtained previously with females taking
other alcoholic beverages [5].
Experiment 5: Estradiol Levels Following Doses of EV
We used 85 females of nearly the same age, weight, and
strain as used in Experiment 1 to 4 to obtain data concern-
ing the levels of circulating estradiol following the single
injections of EV. These females lived for 27 days, or more,
under the same conditions (e.g., food and water always
available, housed individually) in the same room as the
females of Experiments 1 to 4. Just after the trunk blood
was taken, persons unfamiliar with the subjects' group
membership inspected the nipples of the females judging
their size as small, medium or large and the number of
nipples meeting each judgement.
In order to have data applicable to more than this report,
we gave doses in terms of mg/kg. The 10 mg/kg is similar
to the 2.0 mg/rat used in other studies (and Experiments
1–4). The other doses were 7.0 and 3.0 mg/kg (compara-
ble to log units). Samples were taken 4, 12, and 27 days
after injections. Samples were taken from placebo-treated
subjects 27 days after their injections.
The results are summarized in Figure 8. It is clear, and as
expected, the level of circulating estradiol is a function of
size of dose and time after dosing. The levels achieved
after the largest doses are massive in comparison to doses
Weekly Ethanol Intake after Introduction of 18% Ethanol  Solution, Weeks 7 and 8 following Introduction of Opportu- nity to Drink Alcoholic Beverage Figure 6
Weekly Ethanol Intake after Introduction of 18% Eth-
anol Solution, Weeks 7 and 8 following Introduction 
of Opportunity to Drink Alcoholic Beverage. The fig-
ure summarizes intakes during the first two weeks of presen-
tation of 18% ethanol solution. The values are the means of 
the total intake during the four days of each week of the pro-
cedure (n = 10/group). The first day of the 18% beverage was 
57 days after the single injection of EV. Notice that the group 
of placebos reduced their intakes during Week 2, but that 
EV-treated groups did not. Comparisons using t-tests of EV-
treated groups compared to placebo group indicates that no 
group was statistically different than placebo controls (ps > 
0.20). One subject of placebo controls drank more ethanol 
during Week 1 than it had previously and all other subjects. 
At week 2 of the figure, t-tests indicate that each group was 
reliably different from placebo controls, all ps < 0.04.
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that clearly modify the estrous cycle and are large in com-
parison to doses achieved during pregnancy.
None of the placebo-treated rats had enlarged nipples.
When judgements were made on those inspected at 4 days
after injections of EV, none of the females were judged to
have enlarged nipples. When judgements were made of
those of 12 and 27 days after injections of EV (regardless
of dose), all rats were judged to have multiple medium
and large nipples. With no overlap in distributions, there
is statistical significance between placebo-treated and EV-
treated groups and among times of injections for EV-
treated subjects.
Discussion
A potential criticism of these findings is that, by providing
sugar sweetened alcoholic beverage as the alcoholic bever-
age to be assessed, we have confounded taste and calories
with the unique properties of ethanol that might sustain
high levels of intake. This is a cogent criticism, if the goal
of the research was to assess the effects of EV on intake of
ethanol itself rather than the propensity to drink a palata-
ble alcoholic beverage. If one is to assess the drinking of
an alcoholic beverage, there is no way to separate taste
and calories from a beverage containing ethanol. Alco-
holic beverages of water and ethanol have both taste
(probably bitterness covarying with concentration of eth-
anol) and calories. The goal here was to assess the effects
of doses of EV on intake of an alcoholic beverage taken in
large amounts. If we had provided our subjects with
merely ethanol and water, the rats would not have taken
sufficient beverage to achieve considerable blood ethanol
levels. By using a palatable alcoholic beverage, we are
more apt to measure the effects of ethanol because taste
and calories are not limiting the intakes. With the bever-
age used here, it is the ethanol that is limiting intakes (as
demonstrated by the gradual increase in intakes across
weeks) (Figure 2) and is the salient feature of the beverage.
Realizing that these arguments have not convinced those
Intake of Alcoholic Beverage Immediately Following 2 mg of  EV or Placebo Figure 7
Intake of Alcoholic Beverage Immediately Following 
2 mg of EV or Placebo. This figure summarizes the change 
in intakes of two groups of females. Both had been taking 
alcoholic beverage for 4 days a week for 4 weeks before the 
start of this experiment. They continued that regimen for 
another week (Week 1 here, a baseline measure). After 
Week 1, one group received placebos. The other group 
received 10 mg/kg of EV. The data are means of total intake 
taken during the week (across 4 days). The bars represent 
standard errors of the mean. As can be seen by the overlap 
of error bars, the groups did not differ significantly at Week 
1 (baseline). The group of placebo continued to take substan-
tial amounts of ethanol and showed no significant change in 
intakes from Week 1 to 2, p-value for t-test for dependent 
groups = 0.55. As can be seen from the lack of overlap of 
error bars, the groups differed significantly in intake during 
Week 2, p = 0.0005. The dose of EV reduced intakes, p-value 
for t-test for dependent means = 0.003 (Week 1 vs. Week 2, 
EV group).
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Table 1: Estradiol levels
Group Placebo 1 mg EV 2 mg EV 2 mg EV, OVX
Mean (pg/ml) 18.9 12.9 17.6 10.4
Standard Deviation 37.2 15.2 14.5 6.9
Note: The large standard deviation of the placebo group is due to one extra large value (122 pg/ml).BMC Pharmacology 2007, 7:3 http://www.biomedcentral.com/1471-2210/7/3
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who study rats' intake of alcoholic beverage to use highly
palatable beverages, we [5] demonstrated that EV
enhanced intakes of alcoholic beverages when the bever-
age is only ethanol and water (of course, intakes of etha-
nol were much smaller, but the smaller amounts were
enhanced).
The problematic consequences of drinking alcoholic bev-
erages are directly related to the amount of ethanol con-
sumed regardless of the flavour of the beverage. The
beverage used here to some human's taste has a clear taste
of ethanol (it is more than 24% proof) and tastes like after
dinner drinks or fortified wines. Similar drinks are readily
available to women who have been given doses of estro-
genic medicines.
In the group getting 2 mg of EV, there was one subject that
did not drink any alcoholic beverage for a week. It showed
what some have called a neophobia. Another female did
not show the characteristic weight loss associated with
injection of EV (probably some inadvertent failure of the
injection) and its intake was similar to placebo controls.
These two subjects' data are included in the data pre-
sented. If their data were not included, the effects of 2 mg
of EV would appear somewhat larger and more consistent.
The possibility of neophobia can be controlled for by pre-
senting a to-be-tested ingesta before injections for suffi-
ciently long period for all subjects to be taking it.
The initial effects of continuous estradiol are a loss of bod-
yweight (Figure 1) and a reduction in intake of alcohol
(Figure 7) and other ingesta [12,23,24]. If the loss of bod-
yweight signifies a malaise, as other data indicates
[13,14], these initial effects, when paired with discernible
ingesta by way of well-known conditioning mechanisms
might mask the development of what otherwise might be
an enhanced appetite for alcohol or other ingesta. With
the recognition that we might be establishing a condi-
tioned taste aversion, if we paired the initial effects of our
injections with the first presentations of alcoholic bever-
age, we waited 6 days after injections to introduce the rats
to the alcoholic beverage.
It is easy to see, in retrospect, how the usual procedures for
assessing a drug on intake of alcohol, when used while
assessing estradiol, would have produced results leading
to the conclusion that estradiol did not enhance intakes.
Special procedures are needed to observe estradiol's
potential to enhance intake of alcoholic beverages (i.e.,
those involving not pairing the initial effects of estradiol
with initial presentations of the beverage and prolonged
testing allowing sufficient time to have the rats develop
their taste for alcoholic beverage both before and after
application of continuously high levels of estradiol).
When those special procedures are used, continuous
application of estradiol can induce an enlarged appetite
for alcoholic beverages. The results of the relatively few
Estradiol Levels Following a Single Injection of One of Three Doses of Estradiol Valerate Figure 8
Estradiol Levels Following a Single Injection of One of Three Doses of Estradiol Valerate. Serum levels of estradiol 
following single injections of 10.0, 7.0, or 3.0 mg/kg of estradiol valerate. Samples were taken at 4, 12 or 27 days after injections 
of EV. Placebo samples were taken at 27 days after injection of carrier of EV. The 10.0 mg/kg dose is very similar to the 2.0 mg/
female dose given to subjects of Experiment 1. The right panel is an expansion of the data taken 12 days after injections. The 
error bars are standard errors of the mean; the standard error of the mean for placebo scores = 5.1.
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studies that have assessed the effects of injections of estra-
diol on intake of alcoholic beverages lead to the conclu-
sion that the initial effects of estradiol and the continuous
effects are different.
In this experiment, although we did separate the initial
effects of EV from presentation of alcoholic beverage, we
may not have had ideal conditions for seeing the effects of
small doses of EV. The major effects of small doses may
have faded during the time the females were developing
their taste for alcohol. If the smaller doses' effects waned
while the rats were acquiring a taste for the alcoholic bev-
erage, we may have limited the opportunity to see marked
enhancing effects with small doses. Using a regimen for
establishment of stable intakes before injections and then
not pairing the initial effects of EV with the to-be-tested
food, Boswell et al. [28] has shown that small doses of EV
(0.19 mg/kg) enhance intakes of chocolate cake mix bat-
ter when care is taken to control for the initial effects of
EV.
It has been known for some time that opioid receptor
antagonists reduced and opioid receptor agonists
enhanced intake of alcoholic beverages and other ingesta
[25]. Juárez et al. [26] have hypothesized that the initial
effects of estradiol are to downregulate opioid receptors
inducing a state similar to administering an opioid antag-
onist. Following downregulation, it was hypothesized
that a rebound upregulation would induce the effects of
opioid agonists. The idea emerges that the initial effects of
continuous estradiol is one that may reflect a malaise and
a down regulation of opioid receptors producing condi-
tions for reduced intake and potential for conditioned
taste avoidances to novel ingesta. Given that small doses
of morphine (smaller than those inducing analgesia) will
enhance intakes of alcoholic beverages, and do so when
given day after day [27], it is reasonable to hypothesize
that events that might enhance opioidergic tone would
increase intakes. The estrogenic effects may be susceptible
to manipulation by opioidergic drugs during the initial
effects of estradiol; for example, small doses of morphine
may prevent the longer term upregulation of receptors.
Pregnancy is characterized by initiation of prolonged,
high levels of estradiol and is often associated with a fin-
icky approach toward food followed by enhanced appe-
tite [11]. The presence of enlarged nipples in the females
following large doses of EV indicate that the continuous
estradiol made changes that are associated with preg-
nancy.
Based on one perspective, the conclusion to be reached
from our dose response study is that only very large doses
of EV enhanced intakes of alcohol (with one exception,
only the doses of 1 and 2 mg produced scores that were
statistically different than placebo scores). Such a perspec-
tive would push one toward explanations of the effects of
large doses EV in terms of its reputed toxic effects on the
arcuate nucleus of the hypothalamus. If the effect is based
in toxicity of very large doses, maybe the effect is not ger-
mane to conditions of women and their intake of estro-
genic medicines. From another perspective, however,
Juárez et al. [26] recently showed that smaller doses of
estradiol did enhance intakes when opportunities to drink
were not associated with the initial effects of EV. Also, the
dose-orderly effects associated with Figure 3 suggest that
under other circumstances of testing smaller doses might
enhance intakes. The data support the hypothesis that the
enduring effects from a single injection of EV are related
to doses similar in magnitude of 1 and 2 mg/female.
Smaller doses may produce transitory effects.
There are data indicating that women with higher levels of
circulating estradiol drink more than their counterparts
[29,30]. Prior to a small number of some recent studies
[5,9,10,31], including this one, the consensus from labo-
ratory-studies was that estradiol reduced intake of alco-
holic beverages [6,7] and ingesta in general [12,23,24].
Conclusions such as a surfeit of estradiol might enhance
appetite for alcohol that might be derived from the corre-
lations obtained from the epidemiological studies of
women [29,30] were not supported by studies from the
experimental laboratory where estradiol was administered
and intakes of alcohol measured. The newer studies from
the laboratory do indicate that there are circumstances
under which estradiol can enhance intakes of alcoholic
beverages and open the possibility that estrogenic stimu-
lation may enhance appetite for alcohol. A sustained
increased appetite for alcohol, of course, is the condition
of AAA.
When we measured estradiol levels 67 days after injec-
tions, the estradiol levels were very low, so low they were
similar to ovariectomized females. The conclusion that
continuous application of estradiol can induce marked
increases in intake of alcoholic beverage seems contrary to
the finding that toward the end of our testing, subjects
given large doses of EV had estradiol levels that were
small, but intakes of alcohol were large. In other experi-
ments [9,10], about a 100 days after injections, EV-treated
groups were drinking more than the placebo-treated. The
resolution of the apparent conflict, perhaps, resides with
the idea that 2 mg of EV induces supraphysiological levels
of estradiol that eventually lead to disruption of the arcu-
ate nucleus [2]. The idea is that the continuance of high
levels of estradiol, in the relatively short run, and disrup-
tion of the arcuate nucleus due to prolonged high levels of
estradiol are both conditions of high intake of alcoholic
beverages.BMC Pharmacology 2007, 7:3 http://www.biomedcentral.com/1471-2210/7/3
Page 11 of 14
(page number not for citation purposes)
The mean level of circulating estradiol of the placebo-
treated subjects that had no access to alcohol is 53.2 pg/
ml (standard error of mean = 5.1) compared to the pla-
cebo-treated subjects that were on the regimen of alcohol
presentation whose mean is 18.9 (standard error of mean
= 9.3) (p-value associated with a t-test for independent
samples = 0.003) (see Table 1 for other values). The meas-
ures of circulating estradiol were conducted in exactly the
same way, but the females of the alcohol regimen were
somewhat older and had lived a shorter time in individual
cages. Nevertheless, the difference in estradiol levels is
large and suggests that periodic intake of large amounts of
alcoholic beverage might disrupt production of estradiol
in females.
Large doses of EV (2 mg/rat or 10 mg/kg) can provide con-
tinuous, supraphysiological levels of circulating estradiol
for an extended period. To achieve that, however, very
large levels of circulating estradiol are seen initially. EV
surely does not provide constant amounts of estradiol
across a period after injection. The long half-life of EV
indicates that with multiple doses of EV, there could be an
accumulation of estradiol. Two mg doses of EV along with
a progesterone-like drug, given monthly, are the doses
used in birth control drugs touted as effective for use by
women of underdeveloped countries with special refer-
ence to Latin America [32].
Conclusion
These data confirm that a single injection of EV reduces
rate of weight gain in female rats in a dose-orderly way,
with larger doses leading to loss of weight. The disruption
in weight gain is temporary lasting only a matter of days
even following very large doses of EV (e.g., 2.0 mg/
female). There is tolerance to the anorexic effect of estra-
diol as manifest in a return to ordinary rate of weight gain.
These data confirm that an injection of 2.0 mg of EV can
reduce rats' intake of alcoholic beverage when the alco-
holic beverage is presented during the days immediately
following injections even when that intake is primed by
presenting sugar sweetened beverage for a number of days
before injections.
These data confirm that a single injection of 2 mg of EV/
female rat can also induce an enhanced appetite for alco-
holic beverage. The effect can occur with a variety of alco-
holic beverages including 12 and 18% ethanol solutions
sweetened with sugar.
The 2 mg dose of EV can enhance intakes in females with-
out ovaries. This restricts some theories of how EV might
induce its effects.
The very large doses of EV induce correspondingly very
high levels of estradiol that gradually wane with time. At
27 days after dosing, the levels of circulating estradiol are
still at levels ordinarily achieved during pregnancy.
A regimen of inducing periodic large intakes of ethanol
disrupts female rats' production of estradiol in placebo
controls.
The data from the relatively small number of studies
administering estradiol and measuring intake of alcoholic
beverages [5,6,9,10,26,31,33-35], using rodents, are con-
cordant with one another, i.e., all studies show similar
effects. Shortly after injection of a preparation such as EV
or with continuation of dosing by way of multiple injec-
tions of estradiol benzoate, there are reductions in intakes
of alcohol. If, however, the estradiol levels are maintained
at a high level for a number of days, intakes gradually
increase to levels before injection. Further, there are cir-
cumstances under which intakes not only return to base-
line levels but intakes increase to very high levels, higher
than preinjection levels and higher than placebo controls.
These generalizations are apparently not dependent on
strain of rats, whether the females are intact or ovariect-
omized, kind of alcoholic beverage presented during the
testing, or the particular laboratory (and related small
procedural differences) in which the tests were made.
Many circumstances will cause rats to reduce intake of eth-
anol, e.g., anything inducing a malaise. Only a few cir-
cumstances reliably induce significant increases in already
high levels of intake of ethanol, particularly long-lasting
enhanced intakes. Consequently, the findings that estra-
diol can increase intakes might be of interest to those
building theory of alcohol use disorders.
Epidemiological studies[29,30] have shown that women
with high levels of circulating estradiol drink more alco-
hol than their counterparts. These epidemiological results
clashed with the early findings from the experimental lab-
oratory showing that administration of estradiol reduced
intakes of alcohol. The later studies from the experimental
laboratory have now demonstrated that there are circum-
stances under which estradiol can enhance appetite for
alcohol. All of the results converge to support the idea that
the interrelationship between estrogenic processes and
appetite for alcohol should be explored more thoroughly.
This is not only the case because alcohol use disorders
among women are increasing [36], but also because stud-
ies of women show relationships between estrogen levels,
alcoholic intake and breast cancer [37,38].BMC Pharmacology 2007, 7:3 http://www.biomedcentral.com/1471-2210/7/3
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Methods
Subjects
The subjects of Experiment 1 to 4 were 100 female rats
from the colony maintained by the Instituto de Neuro-
biología, UNAM Campus, Juriquilla, Querétero, México.
The rats were derived from the Wistar strain. Upon arrival
at the room of the experiment, they were housed individ-
ually in cages with wood chips on the floor. The room of
the cages was maintained at 21°C and had artificial light-
ing. The lights came on at 10 pm and went off at 10 am.
The lights were turned on, briefly, at 4 pm, to facilitate
removal of the bottles containing alcoholic beverage from
the rats' cages. The rats always had food and water availa-
ble.
The 86 subjects of Experiment 5 were as similar to those
of Experiments 1 to 4 as we could manage. They were of
the same sex, strain, and nearly the same weight when
they were placed in the room in which Experiments 1 to 4
was conducted. The methods and care of the animals were
approved by the institutional care committees of each
institution with which the authors were affiliated.
Doses of EV and Ethanol Solution
EV was purchased from Sigma-Aldrich (St. Louis, MO,
USA). The carrier of EV was sesame seed oil (Sigma-
Aldrich). All injections were 0.2 ml, given intramuscu-
larly. One group, the placebo controls (n = 10), received
only 0.2 ml of oil. Eight other groups (n = 10 each)
received one of eight doses of EV: 0.001, 0.003, 0.01, 0.03,
0.1, 0.3, 1.0 or 2.0 mg/rat. The 2.0 mg dose was the most
characteristic dose used in the experiments assessing EV's
effects on alcohol intake. The dose of 1.0 mg was used in
one experiment and seemed to be effective. The other
doses are graded fractions (in terms of log doses) of the 1
mg dose.
The history of the research dictated the choice of doses,
i.e., we used the dose that was supposedly toxic to the neu-
rons of the arcuate nucleus, i.e., 2 mg/rat [2-4,22]. Notice,
however, that the doses are not precise. The subjects'
weights varied; consequently some subjects received more
EV in terms of mg/kg than others. Also, the rats' weights
change across the period during which estradiol is being
released. In Experiment 5, we gave doses in terms of mg/
kg, i.e., 10, 7 and 3 mg/kg. The 2 mg/female dose used in
most experiments is very similar to 10 mg/kg (i.e., about
200 g is the modal weight of subjects)
The alcoholic beverage was a sucrose-sweetened ethanol
solution. For each 100 g of beverage, there were 12 g of
absolute ethanol (99.8% ethanol), 5 g of sucrose (table
sugar from a local market) and 83 g of water. This bever-
age had been used in other experiments (e.g., [25]) with
male rats. Based on those findings, it was expected that
initially the placebo-controls would take only small
amounts of the beverage, but increase intakes until they
were taking substantial amounts. In one experiment, an
18% ethanol solution was used.
Procedure, Experiment 1
After a few days to habituate to individual caging, the rats
were weighed daily. Ten were selected randomly to receive
ovariectomies. After determining weights of all subjects
across 5 days post surgery, the remaining 90 were assigned
to groups so that the mean weights of the groups were
similar and each group contained 10 subjects. After they
were weighed on the 6th day (mean weight = 223.5 g), all
rats received an injection. Doses were randomly assigned
to groups. The 90 rats received one of nine injections: 0.0
(placebo), 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1.0, or 2.0
mg of EV. Injections were intramuscular in the hip. The
rats of ovariectomies received 2.0 mg.
Six days after injections, all rats were presented with the
sweetened alcoholic beverage from 10 am to 4 pm (initial
hours of darkness). The alcoholic beverage was presented
on Tues., Wed., Thurs., and Fri. of each week. For two
groups (those of 0.001 and 0.003), the procedures
changed at the end of the 5th week (Experiment 3). Testing
was terminated for the groups of 0.03 to 0.3 at the end of
5 weeks of testing. The groups of 2.0 (both intact and
those with ovariectomies), 1.0 mg/kg, and placebos con-
tinued for another week as before, i.e., for a 6th week.
Then, the procedure was changed for the four groups; they
were given 18% ethanol as their alcoholic beverage for
additional 2 weeks of the regimen (Experiment 2).
Procedure, Experiment 2
The weekly regimen of Experiment 1 was continued for 4
groups of subjects just as before except that the alcoholic
beverage that was presented was 18% ethanol (by weight)
rather than 12%. The four groups were those of 2.0 mg of
EV (intact and those with ovariectomies), 1.0 mg of EV
and the placebo controls (0.0 mg of EV). The new alco-
holic beverage was 18 g absolute ethanol, 5 g sucrose and
77 g of water for each 100 g of solution.
Procedure, Experiment 3
At the end of Experiment 2, no further alcoholic beverage
was presented. Beginning week 9 following injections, a
sample of loose cells from the vaginal wall was taken every
day for 12 days during the first hour of dark and placed on
glass slides. The cells were later stained and inspected
microscopically.
After the last acquisition of cells from the vagina, all sub-
jects were sacrificed by decapitation and their trunk-blood
taken for assessment of estradiol levels (see below). With
the taking of blood, an autopsy of the rats with ovariecto-BMC Pharmacology 2007, 7:3 http://www.biomedcentral.com/1471-2210/7/3
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mies was performed with the goal of determining if the
ovaries had, indeed, been removed.
Procedure, Experiment 4
The subjects of this procedure are the subjects of Experi-
ment 1 that received either 0.001 or 0.003 mg of EV. Nei-
ther dose had a reliable effect on rate of gain in
bodyweight or intake of alcoholic beverage. At end of the
5th week of access to alcoholic beverage, one group was
randomly selected to receive placebos (carrier of EV) and
the other 10.0 mg/kg of EV. Group membership was
determined, in part, so that each group had the same
number of subjects of the former group and had similar
intakes of ethanol and bodyweights. The group to receive
EV was determined by the flip of a coin. Injections
occurred on Friday of the 5th set of weekly presentations of
alcoholic beverage and about 2 hr after their usual 6-hr
opportunity to take alcoholic beverage. The schedule of
presentations of alcoholic beverage remained the same as
programmed during the previous 5 weeks for another
week (the week after injections).
Measures of Estradiol in Serum
The samples of trunk blood were from subjects of Experi-
ments 2 and 86 additional subjects. The samples were
allowed to coagulate, thereby providing an initial separa-
tion of plasma from cells. Then, a sample of plasma was
taken and submitted to centrifugation to further separate
dense material from plasma. The plasma was then frozen
and stored at -70°C until assayed for estradiol.
The samples were gradually thawed, e.g., keeping them at
-5°C for 15 minutes then at 4°C for 15 more minutes. The
analysis was done at room temperature. The analyses were
done by use of IMMULITE chemiluminescent counter
using IMMULITE Estradiol kit from Diagnostic Products
Corporation (Los Angeles, CA). This kit has high specifi-
city for the target hormone and low cross-reactivity with
other steroids. IMMULITE Estradiol has 100% specificity
for E2. Cross-reactivity is 0.535% with estriol; 2.09% with
estrone and testosterone is undetectable. Sensitivity goes
from 20 to 2000 pg/ml.
Data-reductions and Statistics
The bottles (equipped with ball point sipping tubes) were
weighed before and after their daily presentations. The
differences in weights, corrected for spillage, are the raw
data for ingestion of alcoholic beverage. The amount to
correct for spillage was determined by placing four or
more bottles on empty cages and taking the mean amount
lost across the measurement period as a correction factor.
The usual amount was less than 1 ml and varied some-
what across days but little across bottles. The rats were
weighed just before presentation of the beverage. Using
these measures, g'E/kg were calculated.
The experimental design for Experiments 1 to 4 conforms
to the factorial design for an analysis of variance
(ANOVA) for repeated measures having factors associated
with the groups of subjects (doses) and periodic measure-
ments of ethanol intake (g'E/kg). When reliable effects
emerged, tests for simple main effects were done. When
there were opportunities for multiple comparisons of
groups' performances, a correction for multiple compari-
sons was used. When comparing some groups' scores,
there was no need for correction for multiple compari-
sons, t-tests were used.
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